Caris Life Sciences Raises $350 million Series G
Caris Life Sciences raised $350M in Series G financing led by Various, with participation from BC Partners. AI tumor profiling for precision oncology. The new capital is framed around Expand liquid biopsy and AI treatment selection globally.
What it does
AI tumor profiling for precision oncology. The business sits in Healthcare & Life Sciences, where funded companies are using fresh capital to deepen product coverage, distribution, or operating capacity.
Traction
Profiled 500,000+ tumors; AI matching improves survival by 18%. Management framed the new capital around Expand liquid biopsy and AI treatment selection globally.
Trend impact
AI molecular profiling replacing single-gene biomarker tests. The capital raise matters because it gives the company more room to compete for customers, talent, and mindshare while incumbents and adjacent startups respond with clearer product depth or distribution.
Funding history
- January 1, 2022 · Series G · $350 million · BC Partners
Products & services
- Healthcare & Life Sciences workflow monitoring tied to the funding announcement
- Customer-facing product described on the company website
- Operational tooling for healthcare & life sciences teams
- Data capture and reporting across core business processes
- Team expansion support funded by the latest round